Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.
In this webinar, Dr. Guido Vranken and product manager Lobke Tremmerie discuss how to implement Bulls XB algorithm, which uses RBC indices to create a weighted moving average of patient sample results, to statistically monitor hematology results. This unique algorithm, offered on Beckman Coulter hematology instruments, allows users to monitor result quality with no additional reagents, software licenses or costs. Laboratories worldwide can implement this simple, powerful tool to enhance results and improve compliance. P.A.C.E. credit is available for your participation.*
Dr. Guido Vranken has been working with customers for over 30 years across different disciplines, including protein chemistry, immunoassay and hematology. He specializes in conducting internal and external validation studies. Dr. Vranken spent three years as a lecturer on statistics at the University of Ghent.
Lobke Tremmerie earned her environmental engineering degree from the University of Ghent in 2002. She first became an electrophoresis and nephelometry sales engineer at Analis, Beckman Coulter’s exclusive Belgian distributor. Following her true passion, she transferred into the hematology division in 2004. Ms. Tremmerie currently serves as Analis’ cellular biology product marketing manager.
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
– The user perspective: perception, adoption and expectations today and tomorrow
– The technology perspective: biggest successes and most room for improvements
– The societal and regulatory perspective: cost and risks versus benefits and opportunities
In this webinar, Dr. Michael Samoszuk discusses the correlative relationships between urine chemistry analytes and the particles noted under the microscope. Attendees will learn how using the knowledge of these correlations can optimize parameter setting for improved laboratory workflow.
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
In this webinar, Dr. Michael Samoszuk will discuss how red blood cell data reported from urine chemistry test strip analysis can correlate to red blood cell data gathered from the microscope, even when the data appears to be conflicting. Attendees will discover some of the underlying factors that could cause this to occur and learn how to minimize reporting inconclusive or inaccurate results.
The CRISPR/Cas genome editing system has revolutionized almost every aspect of the life science industry. Until recently, the most used formats for this technology have been plasmids, mRNA, or lentivirus. Each reagent has been successful in its own right, however, each approach has limitations. SygRNATM, the two-part synthetic crRNA and tracrRNA, increases the pace of research, decreases costs, and can be used with Cas9 protein, Cas9 mRNA and Cas9 expressing cells/models.
This webinar discusses the development of the SygRNATM system, protocol optimization, and proposes workflows that enable scientists to quickly incorporate CRISPR technologies into their research.
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
The masterclass will:
•Introduce demand assessment research and why it is important to healthcare market research
•Discuss how insights from behavioural economics can improve quantitative demand assessment market research
•Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
H&E is the most frequently used stain in histology and is the basis for diagnostics and further selected methods. Thus it is important to have brilliant staining. We will show which minor factors can give a negative effect or spoil the result completely. Tips will be given on improving the sensitivity of the stain. For PAS, we will give advice on how to avoid common errors and always get colourful results.
We will discuss:
•How to prevent "critical situations"
In research areas such as academic, biofuel, food and pharmaceutical industries the determination of algal viability, lipid content, and cell concentration is important in the selection, monitoring, and maintenance of algal cultures. Flow cytometry has been shown to be an ideal method to assess health and lipid content of cultures but has been challenging to adopt due to high complexity and cost of traditional technologies. In this webinar, we present novel simplified methods for algal characterization using microcapillary cytometry on either a simple touch screen based cytometer, the Muse® Cell Analyzer, or a higher throughput cytometric platform, the compact Guava® easyCyte platforms. The MilliporeSigma algae kits utilize simple mix and read protocols, dedicated software modules, and provide quick results for the of count and viability measurements or relative lipid content on algae strains. The optimized and dedicated algae kits allow for high precision and comparable results to predicate methods. Data from applications to multiple common algal strains such as Chlorella vulgaris and Chlamydomonas reinhardti under different culture conditions will be presented. Availability of dedicated kits for algae research on simple and easy to use cytometric platforms will empower and enable algae researchers to rapidly select optimal culture conditions and strains for downstream experiments.
Interaction between antigen-specific T cells and antigen presenting cells (APC) cognate ligand involve reorganization of the cytoskeleton and recruitment of adhesive and signaling molecules to the site of intercellular contact. Sustained adhesion of T cells to APCs and formation of the immunological synapse after T cell receptor stimulation are required for the antigen-specific response. One way to measure an immunological synapse is by fluorescently labeling the molecules that have been recruited to the synapse and imaging by fluorescence microscopy. However, immunological synapses are rare and therefore difficult to analyze objectively and statistically by traditional microscopy methods. To overcome these problems, we employed the Amnis brand imaging flow cytometers to objectively collect imagery of large numbers of cells. We report the percentage of T cells involved in an organized immunological synapse, the recruitment of adhesion molecule LFA-1 and signaling molecule Lck to the synaptic complex and subsequent translocation of NFkB from the cytoplasm to the nucleus in the T cell. In this study, Raji B cells loaded with Staphylococcal enterotoxin B (SEB) were incubated with human T cells to create T cell-APC conjugates. Cells were stained in various combinations for CD3, CD19, Actin, LFA-1, Lck and NFkB. Results from the FlowSight and the ImageStream imaging flow cytometers are compared. Using the FlowSight imaging flow cytometer we demonstrate image-based parameters that were used to assess the frequency of conjugates with an organized immunological synapse in an objective and statistically significant manner. Employing the ImageStream imaging flow cytometer we further evaluate the specific location of the adhesion and signaling molecules LFA-1 and Lck within the immunological synapse complex in T cells and measure the nuclear localization of NFkB in the T cell.
The ImageStream® and FlowSight® are multispectral imaging flow cytometers that generates high resolution images of cells at a rate of 1000’s of cells per second. This allows for the rapid acquisition of tens of thousands of images per sample. Using the IDEAS® image analysis software, the system calculates features based not only on fluorescence intensity but the morphology of that fluorescence as well. This novel approach is able to seamlessly combine the quantitative power of flow cytometry with the high content information associated with microscopy. The system can collect data on a wide range of applications including nuclear localization during a signal transduction cascade, measuring colocalization of two probes, or quantify features on the phagocytosed particles in macrophages.
Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
– How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
– How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
– How real world video content can engage your key stakeholders and ensure customer insights drive action
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.
How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.
UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?
Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.
Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?
In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:
The impact of Brexit on UK Healthcare
The ramification of Brexit for pharma in the UK
What does the Brexit scenario mean for global pharma?
Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement. Learn from their best practice as they share Sanofi Pasteur MSD’s:
· Vision and strategy for digital transformation
· Digital channels (CLM, email) to improve customer engagement
· Deployment of a digital supply chain in ensuring fresh content to channels and content reuse
This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
Join Francis Lacombe, M.D., Ph.D., head of the hematology/automation laboratory and director of flow cytometry at the Université Hôpital, Haut-Lévêque, Pessac, France, to learn how Beckman Coulter’s HematoFlow* and CytoDiff* were instrumental to a recent study that tracked blast decrease rate in acute myeloid leukemia (AML) patients.
In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.
This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.
With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.
As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.
This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
Skin cancer is by far the most prevalent cancer. Each year, approximately 3.4 million people in the US alone are diagnosed with some form of skin cancer. Skin cancer can be highly treatable if it is detected and classified early, and this detection and classification is often aided by immunohistochemistry. This presentation covers many of the basic science, facts, and statistics of skin cancer, as well as the utility of immunohistochemical testing with markers such as S-100, SOX-10, Ber-Ep4, and HHV-8 in the accurate diagnosis and survival rates of skin cancer. Continuing education credits for attending this webinar will be offered through the National Society of Histotechnology
A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 cell lines; the HeLa Mitotrap cell lines; and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applications of the cell lines; The types of companies and institutions we license to; Advantages of partnering with culture experts and specialised distributors; Our experience of working with ECACC and Sigma-Aldrich.
In our webinar, Identifying Men with Significant Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:
• Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening
• Improve your interpretation of a PSA result
• Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy
• Understand how the phi score, combined with family and patient history, can determine patient management decisions
Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.